Entera Bio Price to Free Cash Flow Ratio 2018-2021 | ENTX

Historical price to free cash flow ratio values for Entera Bio (ENTX) since 2018. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Entera Bio Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2021-10-15 4.52 0.00
2021-06-30 5.98 $-0.40 0.00
2021-03-31 3.81 $-0.52 0.00
2020-12-31 1.08 $-0.56 0.00
2020-09-30 1.24 $-0.76 0.00
2020-06-30 1.84 $-0.73 0.00
2020-03-31 2.06 $-0.71 0.00
2019-12-31 2.14 $-0.74 0.00
2019-09-30 2.49 $-0.44 0.00
2019-06-30 3.43 $-0.43 0.00
2019-03-31 4.33 $-0.80 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.107B $0.000B
Entera Bio Ltd. is a clinical-stage biopharmaceutical company. It focused on the development and commercialization of orally delivered molecule therapeutics for use in orphan indications and other areas with significant unmet medical need. The Company is initially applying its technology to develop an oral formulation of parathyroid hormone for hypoparathyroidism and osteoporosis. Entera Bio Ltd. is based in Jerusalem, Israel.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00